Applied NeuroSolutions, Inc. (APNS) is a development-stage biopharmaceutical company with two wholly owned operating subsidiaries. One of the wholly owned operating subsidiaries is Molecular Geriatrics Corporation (MGC), a development-stage biopharmaceutical company that develops diagnostics to detect, and therapeutics to treat Alzheimer's disease (AD). The other wholly owned operating subsidiary is Hemoxymed Europe, SAS, a development-stage biopharmaceutical company that develops therapies aimed at improving tissue oxygenation by increasing oxygen release from hemoglobin to provide therapeutic value to patients with serious, although unmet or underserved, medical needs (the Hemoxygenation technology). The Company is in the process of dissolving these two subsidiaries, and plans to transfer all of their assets to APNS. On October 30, 2003, the Company changed its name from Hemoxymed, Inc. to Applied NeuroSolutions, Inc.